Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Christopher Schott
JPMorgan Chase & Co, Research Division

Good afternoon, everybody. I’m Chris Schott at JPMorgan, and it’s my pleasure to be introducing Amneal today. From the company, we have the company’s Co-CEO, Chirag Patel, who’s going to be doing a presentation, and they’re going to jump into a Q&A session from there. But Chirag, happy New Year.

Chirag Patel
Co-Founder, Co-CEO, President & Director

Thank you for having me here, Chris. Thank you very much for joining us at 4:30 today. But great to see you. I’m very excited to be here. And thank you again to JPMorgan for a wonderful conference here.

So we’re going to jump right into it. We have a lot to share, and I’m going to start just a little history about the founding of Amneal, very humble beginning. My brother is here as well. This time, he comes — we’re co-CEOs, co-founders. Our father helped us with his knowledge, and he’s also pharmaceutical scientists.

And that’s — our humble beginning started in 2002 in Paterson, New Jersey. So we’re a U.S. company dedicated to America, and we have a huge mission, which we will get there. And obviously, it’s much needed in the society as well.

In 23 years, we have delivered so much savings. 175 million prescriptions are filled with Amneal’s products today. Number one in quality, we — that’s our highest priority all the time. All complex dosage forms we have. So we make products from transdermals to in-house injectable to respiratory to topicals, liquid, obviously, oral solids, less and less; and